Introduction
Prostate cancer is one of the most common malignancies in Western males, which accounts for 9% of death in males, and the second leading cause of male cancerrelated death. 1 The standard treatment for advanced or metastatic prostate cancer is androgen deprivation therapy (ADT). 2 Despite the high response rate of ADT, most prostate cancer patients progressed gradually and irreversibly to castration-resistant prostate cancer (CRPC). 3 Docetaxel, the first-line use of chemotherapeutic agents to treat patients with CRPC, has been shown to confer a survival benefit in patients with CRPC. 4, 5 Several other agents, including cabazitaxel (CBZ), 6 enzalutamide (ENZ), 7, 8 abiraterone acetate (AA), 9 ,10 radium-223, 11 and sipuleucel-T, 12 also have been shown to confer a survival benefit in patients with metastatic CRPC (mCRPC). Although some prognostic factors and biomarkers have been reported, a more proper predictive and prognostic biomarker is required to predict the response of patients with CRPCreceived chemotherapy accurately.
Materials and methods literature search
We comprehensively searched PubMed, Embase, Web of Science, and the Cochrane electronic databases for studies published before November 17, 2017 . The search strategy combined key terms related to "castration resistant prostate cancer" or "hormone-refractory prostate cancer" or "androgen independent prostate cancer" or "metastatic prostate cancer" and "Neutrophil to Lymphocyte Ratio" or "NLR" and "prognosis" or "survival" or "outcome" in humans. Two reviewers (ZW and SP) independently screened the titles and abstracts of all initially identified studies according to the selection criteria. Full-text articles of studies that met the following selection criteria were retrieved.
inclusion and exclusion criteria
Inclusion criteria for publication selection were as follows: 1) retrospective studies on the value of NLR in predicting prognosis in castration-resistant prostate cancer patients; 2) the HRs and their 95% CIs for overall survival (OS) or progression-free survival (PFS) analysis were reported in text or could be computed from given data; 3) the value of NLR was obtained for blood sample testing; 4) defined the cutoff value of increased NLR. When multiple reports describing the same population were published, the most recent or complete report was used.
The major exclusion criteria were as follows: abstract, review, case report or comment letter; laboratory studies; animal studies; duplicate publications; published not in English.
Data extraction and quality
Two investigators (ZW and SP) independently extracted data, and a consensus was reached in case of any inconsistency with the involvement of a third author (HX). The following data were extracted from the eligible studies: first author, year of publication, country of origin, median age (range), treatment, median follow-up time, number of elevated NLR, cutoff value, and HR for survival (OS and/or PFS). For articles that only provided survival data in a Kaplan-Meier curve, software designed by Jayne F Tierney and Matthew R Sydes was used to digitize and extract the relative risk and its 95% CI. 25 
statistical analysis
Data were analyzed using Stata SE12.0 (StataCorp LP, College Station, TX, USA). HR with a 95% CI was selected as the effect to measure prognostic outcomes. Study heterogeneity was evaluated using the chi-squared test and
26,27 the value of P heterogeneity <0.1 and I 2 >50% represents significant heterogeneity. The fixed-effects model was used when the value of P heterogeneity >0.1 and I 2 <50%, otherwise the random-effects model was applied. Subgroup analysis was performed for OS and PFS analysis. Begg's funnel plot and Egger's linear regression test were used to evaluate the potential for publication bias. Two-tailed P-value <0.05 was considered statistically significant.
Results

Features of included studies
The selection process for this study is shown in Figure 1 . Through systematic literature searching, a total of 190 potentially relevant studies were identified. Overall, 94 duplicated articles were removed. 61 articles were excluded after screening titles and abstracts, including reviews, letters, meeting abstracts, laboratory studies, and other articles irrelevant to our study. After assessing the full text, 19 additional articles were excluded. Finally, 16 retrospective studies were included in the following meta-analysis.
Summary characteristics of these eligible studies are shown in Table 1 . The 16 selected studies (17 cohorts) published between 2013 and 2017 were included in the metaanalysis. [21] [22] [23] [24] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] The sample size ranged from 33 to 1,224 patients, and a total of 5,705 patients were included. All trials were conducted in adult patients with CRPC. Three studies were conducted in Asian countries (Japan 24, 30 and China 35 ). Thirteen studies were conducted in non-Asian countries, including Italy, 34, 36, 39 UK, 19, 23 Australia, 29, 31 Germany, 21, 22 USA, 37 Turkey, 33 Canada, 38 and the Netherlands. 32 The NLR cutoff value ranged from 2.1 to 5. For the prognostic indicator of NLR in CRPC patients, six articles reported both OS Figure 3B ) and second-line treatment studies (HR=1.97, 95% CI: 1.51-2.57, P<0.001; Table 2, Figure  3C ). For PFS, elevated NLR predicted worse prognosis in cutoff value >3.3 studies (HR=1.87, 95% CI: 1.38-2.54, P<0.001; Table 2, Figure 4A ) and Asian studies (HR=1.99, 95% CI: 1.30-3.06, P=0.002; Table 2, Figure 4B ).
Publication bias
The publication bias in the meta-analysis was assessed by Begg's funnel plots. Funnel plots for meta-analysis of elevated NLR and OS and PFS are shown in Figure 5 . The Begg's funnel plot test (OS: P=0.096, PFS: P=0.230; Figure  5 ) verified that there was no obvious publication bias.
sensitivity analysis
To evaluate the stability of the pooled results, a sensitivity analysis was performed. The result of the sensitivity analysis showed that for OS and PFS, the pooled result did not tend to exhibit alterations when an individual study was excluded ( Figure 6 ).
Discussion
The incidence of prostate cancer has been increasing in the past few years. 40 Most of the prostate cancer patients progressed to CRPC eventually. 3 Several chemotherapeutic agents, including docetaxel, CBZ, ENZ, and AA, have been shown to confer a survival benefit in patients with mCRPC. A more proper predictive and prognostic biomarker is required to predict the response of patients with CRPC-received chemotherapy accurately. It is reported that inflammatory status is associated with the progression of cancer development. 13, 14 The marker of the systemic inflammatory response, NLR, suggests an independent prognostic factor in cancers. [15] [16] [17] [18] NLR has shown to predict poor survival in patients with CRPC. In this metaanalysis, we included 5,705 patients from 16 selected studies (17 cohorts) to evaluate the prognostic role of the NLR in CRPC patients. The pooled results indicated that an elevated NLR is an independent predictor of poor prognosis in CRPC patients.
According to the subgroup analysis, an NLR cutoff value >3.3 had a more significant prognostic value than a cutoff value <3.3 (Table 2) , which indicated that a higher NLR cutoff is more specific to predict a poor prognosis in patients with CRPC. An elevated NLR in Asian group had a more significant prognostic value than that in non-Asian group, indicating that a higher NLR is more specific to predict a poor prognosis in Asian patients with CRPC. Given the limited number of the eligible studies in the meta-analysis, although the pooled results showed that an elevated NLR is associated with a poor prognosis, it will need further investigation to identify that NLR can serve as a clinical marker of prognosis in CRPC patients.
The heterogeneity was relatively small in the included studies. It may be partially explained by nation, sample size, cutoff value, and treatment. And the subgroup analysis showed that the prognostic value of NLR was not affected by the factors included in the analysis. The sensitivity analysis also indicated that the pooled results were relatively conclusive.
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neutrophil-lymphocyte ratio in CRPC patients neutrophils play an important role in tumor progression. 43 In comparison, lymphocytes are critical components of antitumor immunity. 44, 45 NLR is an indicator of systemic inflammatory and immune response of the host; it is also associated with the progression of cancers. [15] [16] [17] [18] NLR can be easily measured from routine CBCs in the peripheral blood, which is low cost, convenient, and reproducible. Moreover, NLR is closely related to the prognosis of CRPC. These reasons indicate that NLR could serve as a prognostic marker for patients with CRPC.
Several meta-analyses have been conducted on the prognosis of NLR for localized prostate cancer and mCRPC; however, the studies included in their meta-analysis were relatively small and the heterogeneity were high. [46] [47] [48] We conducted a comprehensive meta-analysis for the prognostic value of NLR for CRPC, which included 5,705 patients from 16 selected studies (17 cohorts); the pooled results indicated that an elevated NLR is an independent predictor of poor prognosis in patients with CRPC.
Limitations
Several limitations should be acknowledged in the metaanalysis. First, the NLR cutoff value differed among the included studies, potential heterogeneity may exist. Therefore, more studies are required to identify the most suitable NLR cutoff value. Second, NLR could be affected by other diseases, such as inflammatory diseases, infection, renal diseases, and liver diseases. 49, 50 Third, the number of eligible studies in the meta-analysis is relatively small. Finally, studies with positive results are potentially more likely published than work with negative results, which could cause publication bias.
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Conclusion
Our analysis on the currently available clinical evidence suggests that elevated NLR predicted a poor OS and PFS in patients with CRPC. The NLR could serve as an indicator of the efficacy of the treatment of CRPC.
Linton et al (2013) 29 to Sonpavde et al (2014) 37 Templeton et al (2014) 38 Nuhn et al (2014) 21 McLachlan et al (2015) 31 Yao et al (2015) 30 van Soest et al (1) (2015) 32 van Soest et al (2) (2015) 32 Lorente et al (2015) 19 Conteduca et al (2016) 34 Lolli et al (2016) 39 Pei et al (2017) 35 Boegemann et al (2017) 22 Buttigliero et al (2017) 36 Uemura et al (2017) 24 Mehra et al (2017) 31 Pei et al (2017) 35 Boegemann et al (2017) 22 Conteduca et al (2016) 34 Buttigliero et al (2017) 36 Yao et al (2015) 30 Sümbül et al (2014) 
Disclosure
The authors report no conflicts of interest in this work.
